EUVIMEDEUVIMED entdecken
Crossref

Molecular and Behavioral Neuroprotective Effects of Clavulanic Acid and Crocin in Haloperidol-Induced Tardive Dyskinesia in Rats

Parisa Shoae-Hagh, Bibi Marjan Razavi, Hamid Reza Sadeghnia, Soghra Mehri, Gholamreza Karimi, Hossein Hosseinzadeh

Molecular Neurobiology · 2025

DOI: 10.1007/s12035-024-04566-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Neurobiology, 2025. Verfasst von Parisa Shoae-Hagh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Neuroprotective Agents, Haloperidol, Tardive Dyskinesia, Carotenoids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 203 Literaturangaben. Gefördert von: Mashhad University of Medical Sciences Vice-Chancellor for Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clavulanic acid (ClvA), a beta-lactamase inhibitor, is being explored for its significant neuroprotective potential. The effects of ClvA were assessed both individually and in combination with crocin (Cr), an antioxidant derived from saffron, in the context of tardive dyskinesia (TD). In rat haloperidol (Hp)-induced-TD (1 mg/kg, i.p. 21 days), the effects of ClvA (50, 100, 150 mg/kg) and Cr (10, 20, 40 mg/kg) were assessed via vacuous chewing movements (VCM) and tongue protrusion (TP). Striatal malondialdehyde (MDA) and glutathione (GSH) were measured spectrophotometrically. Based on the results, ClvA (100 mg/kg) and Cr (10 mg/kg) were determined with sub-effective doses. Glutamate transporter-subtype1 (GLT1), dopamine active transporter (DAT), vesicular monoamine transporter-type2 (VMAT2), Bax/Bcl2, cleaved Caspase3, phosphorylated AKT/AKT, IL1β, and TNFα levels were quantified using western blotting in sub-effective doses and their combination. The behavioral results of catalepsy and orofacial dyskinesia demonstrated model establishment. Hp decreased GLT1 (p < 0.05), DAT (p < 0.01), VMAT2 (p < 0.001), GSH and pAKT/AKT (p < 0.0001); increased TNFα (p < 0.05), IL1β, cleaved Caspase3 (p < 0.001); MDA and Bax/Bcl2 (p < 0.0001). ClvA 100 mg/kg reversed the decreased GLT1 and VMAT2 (p < 0.01), alongside the increased MDA (p < 0.0001) and VCM (p < 0.05). It also increased AKT phosphorylation (p < 0.05). No effects were noted on DAT, GSH, Bax/Bcl2, or inflammatory factors. However, the combination with Cr at 10 mg/kg influenced ClvA on DAT (p < 0.01) and resulted in a significant increase in GSH (p < 0.0001). Additionally, there was a marked decrease in TNFα (p < 0.0001) and IL1β (p < 0.001), enhancing its effects on reducing MDA and increasing pAKT/AKT (p < 0.0001). The combination adversely affected GLT1. ClvA protects against TD via GLT1 and VMAT2; combined with Cr, it enhances antioxidant effects, improves DAT, and requires dose optimization for GLT1 disruption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroprotective AgentsHaloperidolTardive DyskinesiaCarotenoidsClavulanic AcidBehavior, AnimalAnimalsMaleGlutathioneRatsRats, Sprague-DawleyCorpus StriatumMalondialdehydeProto-Oncogene Proteins c-aktRats, WistarDopamine Plasma Membrane Transport Proteins

Stichwörter der Autor:innen

Dopamine active transporterGlutamate transporterMovement disordersStriatumTardive dyskinesiaVesicular monoamine transporter type 2

Substanzen

Neuroprotective AgentsHaloperidolCarotenoidscrocinClavulanic AcidGlutathioneMalondialdehydeProto-Oncogene Proteins c-aktDopamine Plasma Membrane Transport Proteins

Autor:innen und Institutionen

  • Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. razavimr@mums.ac.ir.
  • Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. razavimr@mums.ac.ir.
  • Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Förderung

  • Mashhad University of Medical Sciences Vice-Chancellor for Research

Zitieren

APA

Shoae-Hagh, P., Razavi, B. M., Sadeghnia, H. R., Mehri, S., Karimi, G., & Hosseinzadeh, H. (2025). Molecular and Behavioral Neuroprotective Effects of Clavulanic Acid and Crocin in Haloperidol-Induced Tardive Dyskinesia in Rats. Molecular Neurobiology. https://doi.org/10.1007/s12035-024-04566-x

Vancouver

Shoae-Hagh P, Razavi BM, Sadeghnia HR, Mehri S, Karimi G, Hosseinzadeh H. Molecular and Behavioral Neuroprotective Effects of Clavulanic Acid and Crocin in Haloperidol-Induced Tardive Dyskinesia in Rats. Molecular Neurobiology. 2025. doi:10.1007/s12035-024-04566-x

BibTeX
@article{ShoaeHagh2025,
  author = {Shoae-Hagh, Parisa and Razavi, Bibi Marjan and Sadeghnia, Hamid Reza and Mehri, Soghra and Karimi, Gholamreza and Hosseinzadeh, Hossein},
  title = {Molecular and Behavioral Neuroprotective Effects of Clavulanic Acid and Crocin in Haloperidol-Induced Tardive Dyskinesia in Rats},
  journal = {Molecular Neurobiology},
  year = {2025},
  doi = {10.1007/s12035-024-04566-x}
}
Kostenlos starten →